MammaRAD Prevention and prognostic factors of a radioembolization-induced liver disease (REILD)RAD289

MammaRAD Prevention and prognostic factors of a radioembolization-induced liver disease (REILD)RAD289 - MammaRAD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011509

Enrollment

Registered

2017-04-21

Start date

2017-02-17

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C50 C78.7

Interventions

Group 1: A total of 99 patients from January 2007 to December 2016 are to be included in the retrospective evaluation. The group consists of patients with metastatic breast cancer and liver metastases

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of non-resectable liver metastases, from breast cancer (BCLM) Sufficient liver function

Exclusion criteria

Exclusion criteria: Hepatic failure Bleeding Pulmonary shunt of the arteria hepatica Complete occlusion of the portal vein

Design outcomes

Primary

Measure	Time frame
The intensified REILD prophylaxis with enoxaparin, pentoxifylline and ursodeoxycholic acid is superior to classical REILD prophylaxis with prednisolone and ursodeoxycholic acid	—

Secondary

Measure	Time frame
Identification of risk factors for the development of a REILD, recording the frequencies and severity of further complications, response rate of radioembolisation, especially in liver metastases resulting from breast carcinoma, survival time analysis	—

Countries

Germany

Contacts

Public ContactChristel Besseler

Klinik für Radiologie und Nuklearmedizin

christel.besseler@ed.ovgu.de+49-391-6713071

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026